Clinical Trials Logo

Clinical Trial Summary

Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, addition of transarterial chemoembolization (TACE) may be beneficial for controlling intrahepatic tumour. The investigators aimed to compare the efficacy between the sorafenib monotherapy and TACE-sorafenib sequential therapy in HCC patients with EHM.


Clinical Trial Description

Sorafenib is the standard therapy for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, transarterial chemoembolization (TACE) which is a standard therapy for intermediate stage may be beneficial for controlling intrahepatic tumour, thereby providing chance of improving survival in HCC patients with EHM.

The investigators aimed to compare the efficacy between the sorafenib monotherapy and TACE-sorafenib sequential therapy in HCC patients with EHM.

This study is a prospective randomized controlled study being conducted at 6 tertiary hospitals in South Korea. HCC patients with EHM are being enrolled and randomized into sorafenib monotherapy or TACE-sorafenib sequential therapy group. Patients with main portal vein invasion, Child-Pugh class B or C, and history of TACE or previous systemic therapy are being excluded. The sorafenib monotherapy group receives sorafenib immediately after randomization while the TACE-sorafenib group receives 2~4 times of TACE before starting sorafenib. Response evaluation are performed every 2 months, and time to progression (TTP), progression free survival (PFS), median survival time (MST), and overall survival (OS) which is the primary outcome measure will be compared. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03518502
Study type Interventional
Source Korea University
Contact Hyung Joon Yim, M.D.
Phone 82-31-412-6565
Email gudwns21@korea.ac.kr
Status Recruiting
Phase Phase 4
Start date March 1, 2012
Completion date February 28, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03222076 - Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) Phase 2
Active, not recruiting NCT01658878 - An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Phase 1/Phase 2
Not yet recruiting NCT03172559 - Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI) N/A
Recruiting NCT02809534 - A Study of Anlotinib in Patients With Hepatocellular Carcinoma Phase 2
Recruiting NCT02854839 - A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma Phase 2
Recruiting NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Not yet recruiting NCT02743065 - HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China N/A
Recruiting NCT02643173 - Hepatocellular Carcinoma Recurrence and Anesthesia N/A
Active, not recruiting NCT02525380 - Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma Phase 4
Active, not recruiting NCT02534337 - Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma Phase 2/Phase 3
Active, not recruiting NCT02527772 - Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma Phase 2/Phase 3
Terminated NCT02549755 - 11C-acetate for Treatment Response After Radiotherapy for HCC Phase 2
Recruiting NCT02174549 - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Phase 1/Phase 2
Recruiting NCT02243384 - Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma N/A
Recruiting NCT02128958 - Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Phase 2
Recruiting NCT01906216 - Sorafenib Chemoembolization Evaluation Controlled Trial Phase 2/Phase 3
Completed NCT02156700 - Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors N/A
Withdrawn NCT01956864 - Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer Phase 1
Enrolling by invitation NCT01715402 - Optimization of Health Expenditure in Liver Surgery N/A
Terminated NCT01668017 - A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy Phase 1